NKTR – nektar therapeutics (US:NASDAQ)
Stock Stats
News
Nektar Therapeutics (NASDAQ: NKTR) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $6.50 price target on the stock.
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting [Yahoo! Finance]
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
Ampersand Capital Partners Completes Acquisition of Nektar Therapeutics' PEG Reagent Manufacturing Business, Launching Newly Branded Gannet BioChem [Yahoo! Finance]
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence [Yahoo! Finance]
Form 4 NEKTAR THERAPEUTICS For: Dec 23 Filed by: Wilson Mark Andrew
Form 144 NEKTAR THERAPEUTICS Filed by: Wilson Mark Andrew
Form 144 NEKTAR THERAPEUTICS Filed by: Wilson Mark Andrew
Form 4 NEKTAR THERAPEUTICS For: Dec 19 Filed by: Zalevsky Jonathan
Form 4 NEKTAR THERAPEUTICS For: Dec 17 Filed by: ROBIN HOWARD W
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.